ABOUT US
Executive
Statement
Lextro Bio Solutions offers next-generation technologies in the field of drug discovery, and development, which includes basic and translational research. We help our customers and collaborators meet the needs of their patients awaiting in all weather.
VISION
To develop sustainable and innovative solutions for a healthy and thriving world through scientific rigor and innovative practices
MISSION
Our mission is to provide solutions for expediting customers life science research, facilitating the development of quality therapeutics with our strong scientific knowledge and technical skills, contributing to a healthier world.
VALUES
Innovation:
Staying on the cutting edge of biotechnology, and finding new and better ways to solve problems and create value for our customers
Quality:
Placing a premium on precision, reliability, and performance to ensure that our solutions consistently exceed the highest standards of excellence
Integrity:
Prioritizing honesty, transparency, and ethical behaviour in all our interactions and dealings with customers, stakeholders and employees
Collaboration:
Coming up with the best possible solutions by engaging in co-creation with customers and knowledge institutions to positively impact the society
Srinivas Akkina
Managing Director
From the
Chairman’s Desk
Bridging science and compassion
to
create life-saving solutions
At our core, we believe that science is the key to unlocking new medical breakthroughs that can save lives and improve the quality of life for millions of people around the world.
We strive to make a difference by positively impacting our customers and partners through accelerated innovative solutions that are safe and effective.
The abiding focus on futuristic technologies fuels our passion to stay ahead of the curve and drive significant advancements in the field of biotech.
Our
Technical Team
Our technical team is comprised of a highly skilled and experienced professionals. Their collective experience spans a wide range of therapeutic domains such as immune therapies of oncology, autoimmune, infectious diseases and metabolic disorders.
Having trained in the top-tier institutions of the world, they bring to the table international exposure and a global perspective on biotech R&D. This allows Lextro to approach challenges with a broad and innovative mindset, leading to breakthrough solutions and cutting-edge technologies.
Dr. Murali K Addepalli
Chief Scientific Officer
Dr. Murali K Addepalli (Murali) has 20+ years’ experience in drug discovery and development of novel immune-therapeutics for oncology, autoimmune and infectious diseases. After obtaining his PhD from Nagasaki University (Japan), he gained valuable experience at NIH, Bethesda (USA) as a Post-doctoral Fellow. He has a proven track record of creating therapeutic pipelines and generating a significant IP portfolio (9 patents) at leading Big Pharma companies including Nektar Therapeutics, Biocon Bristol Myers Squibb and Reliance Life Sciences. He worked in 15+ discovery programs in various capacities, including Biology Lead, Program Lead, and was instrumental in several IND filings.
On the scientific side, Murali has amassed experience in the areas of recombinant therapeutic protein expression, translational research for understanding MoA as well as biomarker discovery, vaccine development, design of molecules using in-silico approaches and tools, development of novel therapeutic monoclonal antibodies from natural & random paired libraries, and NCE & NBE screening in PDO & PDX models. He has special interest in designing new concepts in drug discovery and repurposing drugs. He has more than 25+ publications in reputed journals such as J Immunother Cancer, Nature Commun., Clin. Cancer. Res., Gene therapy, Angiogenesis etc.
On the management side, he is responsible for P&L of contract/custom research projects, has expertise in management and delivery of large global discovery programs, and contributes to optimizing outsourcing strategies to CROs and expediting research timelines.
During his tenure as the Chairperson of IACUC and Biosafety Committee, he was instrumental in securing AAALAC for the host organization. He also oversaw the IND filings to meet FDA requirements, evaluated the in-licensing of molecules and technologies and participated in the out-licensing activities.
Tej Kumar Madineni
Msc
Associate Vice President
Dr. Narasimhulu Simma
PhD
Sr. Scientist
Shalini Kolarkar
MSc
Scientist